INTERFACE BIOLOGICS, INC.
Interface Biologics, Inc. (IBI) is a commercial stage company that develops transformative biomedical polymer technology to improve the safety and effectiveness of medical devices. Their patent-protected technologies include anti-thrombogenic additives for blood contacting medical devices and polymer enabled combination drug delivery devices. IBI has exclusive Endexo™ technology licensing agreements with AngioDynamics for vascular access catheters and with Fresenius Medical Care for chronic... dialysis systems. AngioDynamics’ BioFlo PICCS, Ports and DuraMax Dialysis Catheter with IBI’s Endexo technology have received FDA clearance and are gaining commercial traction. IBI also has a joint venture commercial agreement with Qualimed to develop a drug-coated balloon based on IBI’s Kinesyx™ technology. The company was founded in 2001 and is headquartered in Toronto, Canada at the acclaimed MaRS Innovation Centre.
INTERFACE BIOLOGICS, INC.
Social Links:
Industry:
Biotechnology Health Care Medical Device
Founded:
2001-12-01
Address:
Toronto, Ontario, Canada
Country:
Canada
Website Url:
http://www.interfacebiologics.com
Total Employee:
11+
Status:
Active
Contact:
4169771329
Email Addresses:
[email protected]
Total Funding:
32 M USD
Technology used in webpage:
SPF Euro Microsoft Exchange Online Amazon Office 365 Mail GoDaddy DNS Amazon Virginia Region
Similar Organizations
Altaviz
Altaviz develops patent-protected technologies for single-use, custom injection system medical devices.
Aortech International
Aortech International is a biomedical polymer technology, components and medical devices.
Perikinetics
Perikinetics develops an artificial pancreas technology platform to deliver insulin physiologically.
Preciva
Preciva is developing electronic screening tools to give every woman an equal chance to live free of cervical cancer.
Retractable Technologies
Retractable technologies aim to be a catalyst through creativity, education and the production of secure and effective medical devices.
Xillix
Xillix has develops and commercializes medical imaging technologies for detection and localization of cancer.
Current Advisors List
Founder
Investors List
BDC Healthcare Venture
BDC Healthcare Venture investment in Series B - Interface Biologics, Inc.
DSM Venturing
DSM Venturing investment in Series B - Interface Biologics, Inc.
Business Development Bank of Canada
Business Development Bank of Canada investment in Series B - Interface Biologics, Inc.
Covington Group
Covington Group investment in Series B - Interface Biologics, Inc.
BDC Capital Corporation
BDC Capital Corporation investment in Venture Round - Interface Biologics, Inc.
Covington Group
Covington Group investment in Venture Round - Interface Biologics, Inc.
BDC Venture Capital
BDC Venture Capital investment in Seed Round - Interface Biologics, Inc.
Official Site Inspections
http://www.interfacebiologics.com
- Host name: smtp2.innovasium.com
- IP address: 107.21.8.129
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Interface Biologics, Inc."
Interface Biologics, Inc. - Crunchbase Company Profile & Funding
Interface Biologics, Inc. (IBI) is a commercial stage company that develops transformative biomedical polymer technology to improve the safety and effectiveness of medical devices. …See details»
Interface Bio
At the interface of Human Biology and AI. Complex diseases like autoimmune disorders and cancer require multi-mechanism therapies (e.g. ADCs, bi-specifics), but developing these drugs is challenging due to interaction effects, toxicity, …See details»
Interface Biologics Inc Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Interface Biologics Inc of Toronto, ON. Get the latest business insights from Dun & Bradstreet.See details»
Interface Biologics 2025 Company Profile: Valuation, …
Interface Biologics’s primary industry is Drug Delivery. Is Interface Biologics a private or public company? Interface Biologics is a Private company. What is …See details»
Interface Biologics - LinkedIn
Interface Biologics is a commercial stage privately held company that develops transformative biomedical polymer technology to improve the safety and effectiveness of medical devices.See details»
Interface Biologics Company Overview, Contact Details
Interface Biologics is a commercial stage privately held company that develops transformative biomedical polymer technology to improve the safety and effectiveness of medical devices. …See details»
Interface Biologics - 2025 Company Profile - Tracxn
Mar 7, 2025 Interface Biologics is a biomaterials company that develops and markets polymer technologies programmed at the nano level. It improves the biocompatibility of existing …See details»
Interface Biologics - VentureRadar
Interface Biologics is a commercial stage company that develops innovative materials for improving the efficacy of medical devices and targeted delivery of drugs. Our surface …See details»
Interface Biologics - Craft
Interface Biologics is a developer of transformative biomedical polymer technology solutions that improve the safety and effectiveness of medical devices. Its primary technology focus areas …See details»
Interface Biologics - Overview, News & Similar companies
Nov 26, 2018 Interface Biologics Announces New V.P., Business Development TORONTO, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Interface Biologics Inc. (“IBI”), a privately held, …See details»
Interface Biologics - Company Profile & Staff Directory - ContactOut
Interface Biologics is a commercial stage privately held company that develops transformative biomedical polymer technology to improve the safety and effectiveness of medical devices. …See details»
Interface Biologics - Products, Competitors, Financials, Employees ...
08/30 0 Message : September 3, 2019 Evonik acquires a surface modification technology platform from Interface Biologics to further expand its medical device capabilities Endexo® platform …See details»
Interface Biologics Inc. | BDC.ca
Interface Biologics is a privately held early commercial stage company that develops transformative biomedical polymer technology to improve the safety and effectiveness of …See details»
INTERFACE BIOLOGICS INC | TREA
Antithrombogenic hollow fiber membranes and filters. Patent number 11,766,511; Issue date Sep 26, 2023; Interface Biologics, Inc. Sanjoy MullickSee details»
Nextsource | Company Profile | Interface Biologics, Inc.
Uncover shifts in customer sentiment around Interface Biologics, Inc. through recent reviews or social media mentions. Get detailed insights into the financial health of Interface Biologics, Inc. …See details»
Interface Biologics: Employee Directory | ZoomInfo.com
Interface Biologics (IBI) is an early commercial stage privately held company that develops innovative materials for Medtech and Pharmaceutical applications. IBI surface modification …See details»
Interface Biologics, Inc. - Contacts, Employees, Board Members ...
Interface Biologics develops transformative biomedical polymer technology to improve the safety and effectiveness of medical devices. New. Resources. Advanced Search. ... Log In. …See details»
Evonik purchases surface-modification business unit from Interface ...
Sep 3, 2019 “This is an exciting time for our organization”, stated Tom Reeves, President & CEO of Interface Biologics, Inc. “The sale of our Surface Modification business to Evonik is the …See details»
Interface Biologics to focus future growth in biotech with local …
Feb 5, 2019 By Len Zehr. Closely-held Interface Biologics, best known for improving the safety and efficacy of medical devices through its Endexo surface modification technology, is pegging …See details»
Multimodal SARS-CoV-2 interactome sketches the virus-host …
2 days ago Modeling the spatial organization of SARS-CoV-2-host proteome from the proximal interactome. Since BioID bait proteins label proximal partners within a volume of ~10–20 nm …See details»